
    
      This is a double-blind, double-dummy, multicenter, randomized, active-controlled, parallel
      group, outpatient, safety study to evaluate the long term safety of arformoterol in the
      treatment of subjects with COPD. Study participation will be over approximately 6 months.
      This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired
      by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to
      Sunovion Pharmaceuticals Inc.
    
  